Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Nuclear Medicine Imaging and Therapy in Prostate Cancer
share announcement

Nuclear Medicine Imaging and Therapy in Prostate Cancer

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 821

Special Issue Editors

Prof. Dr. Laura Evangelista

E-Mail Website
Guest Editor
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy
Interests: nucleare medicine; PET/CT; SPECT/CT; radionuclide therapy
Special Issues, Collections and Topics in MDPI journals
Dr. Priscilla Guglielmo

E-Mail Website
Guest Editor
Nuclear Medicine Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy
Interests: molecular imaging; nuclear medicine; lung cancer; prostate cancer; neuroendocrine tumors; PET/CT; PET/MRI; lymphoma; radioligand therapy
Special Issues, Collections and Topics in MDPI journals
Dr. Luca Urso

E-Mail Website
Guest Editor
Department of Nuclear Medicine PET/CT Centre, S. Maria della Misericordia Hospital, 45100 Rovigo, Italy
Interests: molecular imaging; PET; breast cancer; prostate cancer; neuroendocrine tumors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to submit a manuscript to this Special Issue of Diagnostics entitled “Nuclear Medicine Imaging and Therapy in Prostate Cancer”. Prostate cancer is the most common non-cutaneous malignancy among men and is an urgent public health issue.

Nuclear medicine imaging plays a key role in many clinical settings of prostate cancer, with numerous radiotracers available or under investigation. Such advancements in diagnostic imaging and therapy, together with the introduction of artificial intelligence technology in clinical practice, will accelerate the advent of true personalized medicine.

In this Special Issue of Diagnostics, we plan to address the complexity of molecular imaging and theranostics in prostate cancer. We prioritize high-quality original studies, encourage the submission of multidisciplinary works, and welcome well-designed meta-analyses and reviews.

Dr. Laura Evangelista
Dr. Priscilla Guglielmo
Dr. Luca Urso
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • 18F-FDG PET/CT or PET/MRI
  • 68Ga-PSMA PET/CT or 18F-PSMA PET/CT or PET/MRI
  • 18F-choline PET/CT
  • 18F-FACBC
  • theranostics
  • beta-based therapy
  • alpha-based therapy
  • radiomics and artificial intelligence

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 11777 KiB  
Article
68Ga-PSMA PET/CT in Recurrent Prostate Cancer after Radical Prostatectomy Using PSMA-RADS Version 2.0
by Gabriele Masselli, Saadi Sollaku, Cristina De Angelis, Elisabetta Polettini, Gianfranco Gualdi and Emanuele Casciani
Diagnostics 2024, 14(12), 1291; https://doi.org/10.3390/diagnostics14121291 - 19 Jun 2024
Viewed by 511
Abstract
Background: 68Ga-PSMA PET/CT is superior to standard-of-care imaging for detecting regional and distant metastatic recurrent prostate cancer. The objective of our study was to evaluate the performance of 68Ga-PSMAPET/CT in our patient population, using the new PSMA-RADS version 2.0. Methods: A [...] Read more.
Background: 68Ga-PSMA PET/CT is superior to standard-of-care imaging for detecting regional and distant metastatic recurrent prostate cancer. The objective of our study was to evaluate the performance of 68Ga-PSMAPET/CT in our patient population, using the new PSMA-RADS version 2.0. Methods: A total of 128 patients scanned with 68Ga-PSMA PET/CT for detection of recurrence after RP were analyzed with PSMA-RADS version 2.0. For the analysis of the detection rate, categories PSMA-RADS 3 to 5 were considered as “positive for malignancy” and 1–2 as “negative”. Results: According to PSMA-RADS v2.0, we classified patients as follows: 23 patients without PSMA-RADS because they were negative; PSMA-RADS 1: 10 patients; PSMA-RADS 2: 4 patients; PSMA-RADS 3A: 11 patients; PSMA-RADS 3B: 2 patients; PSMA-RADS 3C: 2 patients; PSMA-RADS 3D: 2 patients; PSMA-RADS 4: 13 patients; PSMA-RADS 5: 61 patients. Conclusions: The overall detection rate of 68Ga-PSMA PET/CT was 71%. By dividing the patients into fourgroups according to PSA level before examination, we obtained the following detection rates: PSA < 0.2 ng/mL 38%; 0.2 ≤ PSA < 0.5 ng/mL 57%; 0.5 ≤ PSA ≤ 1 ng/mL 77%; and PSA > 1 ng/mL 95%. Conclusion: Using PSMA-RADS version 2.0, we obtained detection rate values comparable with recent literature both in absolute terms and in relation to different PSA levels. Full article
(This article belongs to the Special Issue Nuclear Medicine Imaging and Therapy in Prostate Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop